Myasthenia Gravis – RNAC-MG-002
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Inclusion Criteria:
- Patient must be at least 18 years of age.
- Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening.
- MG-Activities of Daily Living (MG ADL) total score ≥ 6.
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
